Roche Launches Newborn Screening Test for SMA, SCID, SCD
Roche launches a CE-marked newborn screening test that detects SMA, SCID and sickle cell disease in one assay on LightCycler systems; not sold in the US.
Roche Launches Newborn Screening Test for SMA, SCID, SCD
Roche launches a CE-marked newborn screening test that detects SMA, SCID and sickle cell disease in one assay on LightCycler systems; not sold in the US.
Rakovina and Celvion Partner on AI-Driven Cancer Therapy
Rakovina Celvion partnership uses the EMphora AI platform and real-world clinical data to guide ATR inhibitor development; no financial terms disclosed.
Ensera Launches Alliance Network for Combination Products
Ensera alliance network links SHL Medical, Stevanato, Ypsomed, Argonaut and American Injectables to speed drug-device combination product supply.
Artificial Organs Market to Top $63 Billion by 2035
Artificial organs market size was $28.71 billion in 2025 and is projected to top $63.31 billion by 2035 at an 8.2% CAGR, led by North America.
AI in Neurosurgery Market to Reach $11.3 Billion by 2035
AI in neurosurgery market size was $850 million in 2025 and is forecast to hit $11.3 billion by 2035 at a 29.5% CAGR, led by North America and software.
AI in Healthcare Market to Reach $1.14 Trillion by 2035 at 39.1% CAGR
The AI in healthcare market was valued at $41.84 billion in 2025 and is projected to top $1.13 trillion by 2035, growing at a 39.1% CAGR led by North America.
Terumo Neuro Arsenal Medical Deal Adds Liquid Embolic
Terumo Neuro Arsenal Medical deal: Terumo Neuro agreed to buy Arsenal Medical and its NeoCast liquid embolic for chronic subdural hematoma.
Tulisokibart Hidradenitis Suppurativa Trial Meets Endpoint
Tulisokibart hidradenitis suppurativa results: Merck’s Phase 2b trial met its HiSCR50 primary endpoint at week 16, with 72% response on the high dose.
FDA Accepts Roche’s Fenebrutinib NDA with Priority Review for Relapsing and Primary Progressive MS
The U.S. Food and Drug Administration has accepted Roche’s New Drug Application for fenebrutinib and granted the drug Priority Review designation for two forms of multiple sclerosis: relapsing multiple sclerosis and primary progressive multiple sclerosis. Roche announced the regulatory milestone on September 30, 2026. The PDUFA target action date, the deadline by which the FDA…
